Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two early papers expressing conflicting views on the occurrence of effective immune attack against cancers stimulate an analysis of the gradual development of an understanding of tumour biology. This understanding has led to the development of the strikingly effective check point blocking and CART anti-cancer immunotherapies, and the promise of more widely applicable therapies based on T cell attracting genetically engineered monoclonal antibodies.

Original publication

DOI

10.1038/s41416-022-02075-z

Type

Journal article

Journal

British journal of cancer

Publication Date

12/2022

Addresses

Weatherall Institute of Molecular Medicine, Department of Oncology, University of Oxford, Oxford, UK. walter.bodmer@hertford.ox.ac.uk.